Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn's disease.

MLA

Oike, Tsubasa, et al. “Efficacy and Safety of Biosimilar Infliximab in Bio-Naïve Patients with Crohn’s Disease.” Arab Journal of Gastroenterology : The Official Publication of the Pan-Arab Association of Gastroenterology, vol. 25, no. 3, Aug. 2024, pp. 257–62. EBSCOhost, https://doi.org/10.1016/j.ajg.2024.03.006.

APA

Oike, T., Akizue, N., Ohta, Y., Koseki, H., Saito, M., Yokoyama, Y., Imai, Y., Taida, T., Okimoto, K., Saito, K., Ogasawara, S., Matsumura, T., Nakagawa, T., Arai, M., Katsuno, T., Fukuda, Y., Kitsukawa, Y., Kato, J., & Kato, N. (2024). Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease. Arab Journal of Gastroenterology : The Official Publication of the Pan-Arab Association of Gastroenterology, 25(3), 257–262. https://doi.org/10.1016/j.ajg.2024.03.006

Chicago

Oike, Tsubasa, Naoki Akizue, Yuki Ohta, Hirotaka Koseki, Masaya Saito, Yuya Yokoyama, Yushi Imai, et al. 2024. “Efficacy and Safety of Biosimilar Infliximab in Bio-Naïve Patients with Crohn’s Disease.” Arab Journal of Gastroenterology : The Official Publication of the Pan-Arab Association of Gastroenterology 25 (3): 257–62. doi:10.1016/j.ajg.2024.03.006.